Sam is the president of Agilent's Diagnostics and Genomics Group. He is responsible for overall strategy, along with business and financial results, for the group which includes the pathology, genomics, companion diagnostics, and Nucleic Acid Solutions (therapeutic oligonucleotides) businesses.
Sam returned to Agilent in early 2017 to lead the Strategy and Corporate Development function. He led the creation of Agilent's first long range strategy while strengthening Agilent's M&A capabilities, overseeing numerous acquisitions that strategically enhanced Agilent's offerings to customers.
Prior to re-joining Agilent, Sam was vice president of global marketing at Illumina, a San Diego-based life sciences company. He was responsible for leading the overall marketing function for Illumina including product management, clinical marketing, and corporate marketing. He was an integral part of defining a multi-year sequencing platform road-map and successfully launched several sequencing systems and consumables to drive market defining growth.
Prior to his years at Illumina, Sam was vice president and general manager of the genomic assays business unit at Life Technologies, with P&L responsibility for the TaqMan™ franchise and next generation qPCR instruments and solutions.
Earlier in his Agilent career, Sam was vice president and general manager of the Americas with responsibility for sales, regional marketing, and customer and applications support for the Life Sciences and Chemical Analysis Group.
Sam earned his MBA from Santa Clara University and has an undergraduate degree in molecular and cell biology from the University of California, Berkeley.
How do I contact Samraat S. Raha?
Has Samraat S. Raha been buying or selling shares of Agilent Technologies?
Samraat S. Raha has not been actively trading shares of Agilent Technologies in the last ninety days. Most recently, Samraat S. Raha sold 1,000 shares of the business's stock in a transaction on Wednesday, March 31st. The shares were sold at an average price of $127.50, for a transaction totalling $127,500.00. Learn More on Samraat S. Raha's trading history.
Who are Agilent Technologies' active insiders?
Agilent Technologies' insider roster includes Henrik Ancher-Jensen (SVP), Philip Binns (SVP), Heidi Fields (Director), Rodney Gonsalves (VP), Dominique Grau (SVP), Boon Koh (Director), Padraig Mcdonnell (VP), Michael Mcmullen (CEO), Samraat Raha (VP), Michael Tang (SVP), and Jacob Thaysen (VP). Learn More on Agilent Technologies' active insiders.
Are insiders buying or selling shares of Agilent Technologies?
In the last twelve months, Agilent Technologies insiders bought shares 1 times. They purchased a total of 3 shares worth more than $333.27. In the last twelve months, insiders at the medical research company sold shares 11 times. They sold a total of 161,983 shares worth more than $22,489,381.86. The most recent insider tranaction occured on March, 25th when SVP Philip Binns sold 2,827 shares worth more than $417,095.58. Insiders at Agilent Technologies own 0.3% of the company.
Learn More about insider trades at Agilent Technologies. Information on this page was last updated on 3/25/2024.
